Vor Biopharma (NASDAQ:VOR) Shares Down 5.8% on Insider Selling

Vor Biopharma Inc. (NASDAQ:VOR) shares traded down 5.8% during trading on Monday following insider selling activity. The stock traded as low as $17.11 and last traded at $17.0040. 211,115 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 965,964 shares. The stock had previously closed at $18.05.

Specifically, Director Ra Capital Management, L.P. sold 589,257 shares of the business’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $16.59, for a total value of $9,775,773.63. Following the completion of the transaction, the director owned 4,555,741 shares of the company’s stock, valued at approximately $75,579,743.19. The trade was a 11.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ra Capital Management, L.P. sold 260,000 shares of the business’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $18.23, for a total value of $4,739,800.00. Following the completion of the transaction, the director directly owned 5,144,998 shares of the company’s stock, valued at approximately $93,793,313.54. This trade represents a 4.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Wells Fargo & Company assumed coverage on Vor Biopharma in a research report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 target price for the company. Wall Street Zen raised Vor Biopharma from a “strong sell” rating to a “hold” rating in a research report on Saturday. TD Cowen assumed coverage on Vor Biopharma in a research report on Wednesday, December 17th. They issued a “buy” rating for the company. Jefferies Financial Group assumed coverage on Vor Biopharma in a research report on Monday, March 30th. They issued a “buy” rating and a $50.00 target price for the company. Finally, Wedbush boosted their target price on Vor Biopharma to $15.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $50.67.

Vor Biopharma Price Performance

The company has a market cap of $823.09 million, a PE ratio of -0.04 and a beta of 1.92. The business has a 50-day moving average of $14.29 and a 200 day moving average of $17.27.

Institutional Trading of Vor Biopharma

A number of hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. increased its position in Vor Biopharma by 172.7% during the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock valued at $70,697,000 after acquiring an additional 3,422,697 shares during the last quarter. Fcpm Iii Services B.V. grew its holdings in Vor Biopharma by 852.8% during the fourth quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock valued at $47,315,000 after purchasing an additional 3,237,714 shares during the period. Frazier Life Sciences Management L.P. bought a new stake in Vor Biopharma during the fourth quarter valued at about $33,275,000. Paradigm Biocapital Advisors LP bought a new stake in Vor Biopharma during the fourth quarter valued at about $22,890,000. Finally, NEXTBio Capital Management LP bought a new stake in Vor Biopharma during the fourth quarter valued at about $13,080,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).